Matching articles for "ADHD"

In Brief: Alternatives to Adderall

   
The Medical Letter on Drugs and Therapeutics • November 28, 2022;  (Issue 1664)
The short-acting formulation of mixed amphetamine salts (Adderall, and generics) FDA-approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy, is currently in short supply...
The short-acting formulation of mixed amphetamine salts (Adderall, and generics) FDA-approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy, is currently in short supply in the US. Until an adequate supply is restored, patients may be looking for alternatives.
Med Lett Drugs Ther. 2022 Nov 28;64(1664):191-2 | Show Full IntroductionHide Full Introduction

Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD

   
The Medical Letter on Drugs and Therapeutics • October 4, 2021;  (Issue 1634)
The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate (Azstarys – Corium) for once-daily treatment of...
The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate (Azstarys – Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Azstarys is the first product containing serdexmethylphenidate to become available in the US.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):157-9 | Show Full IntroductionHide Full Introduction

Melatonin for Insomnia in Children

   
The Medical Letter on Drugs and Therapeutics • June 29, 2020;  (Issue 1601)
...
Over-the-counter products containing melatonin are widely used as sleep aids in children and adults.
Med Lett Drugs Ther. 2020 Jun 29;62(1601):103-4 | Show Full IntroductionHide Full Introduction

Drugs for ADHD

   
The Medical Letter on Drugs and Therapeutics • January 27, 2020;  (Issue 1590)
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study...
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of serious traffic accidents and criminal behavior.4-6 Drugs approved by the FDA for treatment of ADHD are listed in Table 1.
Med Lett Drugs Ther. 2020 Jan 27;62(1590):9-15 | Show Full IntroductionHide Full Introduction

Jornay PM - Evening-Dosed Methylphenidate for ADHD

   
The Medical Letter on Drugs and Therapeutics • August 12, 2019;  (Issue 1578)
The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit...
The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients >6 years old. Jornay PM is the first methylphenidate product to become available in the US that is taken in the evening; other long-acting methylphenidate formulations are taken in the morning. It is being marketed specifically for patients who have disruptive ADHD symptoms in the morning.
Med Lett Drugs Ther. 2019 Aug 12;61(1578):126-8 | Show Full IntroductionHide Full Introduction

A New Amphetamine Oral Suspension (Adzenys ER) for ADHD (online only)

   
The Medical Letter on Drugs and Therapeutics • June 18, 2018;  (Issue 1549)
The FDA has approved an extended-release oral suspension formulation of amphetamine (Adzenys ER – Neos) for treatment of attention deficit hyperactivity disorder (ADHD) in patients ≥6 years old. The...
The FDA has approved an extended-release oral suspension formulation of amphetamine (Adzenys ER – Neos) for treatment of attention deficit hyperactivity disorder (ADHD) in patients ≥6 years old. The same extended-release amphetamine product is available as an orally disintegrating tablet and is marketed as Adzenys XR-ODT. Another extended-release oral suspension formulation of amphetamine, Dyanavel XR, was approved earlier.
Med Lett Drugs Ther. 2018 Jun 18;60(1549):e106-8 | Show Full IntroductionHide Full Introduction

Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD

   
The Medical Letter on Drugs and Therapeutics • November 6, 2017;  (Issue 1533)
The FDA has approved an extended-release orally disintegrating tablet formulation of methylphenidate (Cotempla XR-ODT – Neos Therapeutics) for once-daily treatment of attention-defi...
The FDA has approved an extended-release orally disintegrating tablet formulation of methylphenidate (Cotempla XR-ODT – Neos Therapeutics) for once-daily treatment of attention-defi cit/hyperactivity disorder (ADHD) in children 6-17 years old. Cotempla XR-ODT is the first extended-release orally disintegrating tablet formulation of methylphenidate to become available in the US.
Med Lett Drugs Ther. 2017 Nov 6;59(1533):183-5 | Show Full IntroductionHide Full Introduction

Two New Amphetamines for ADHD

   
The Medical Letter on Drugs and Therapeutics • June 20, 2016;  (Issue 1497)
Two new extended-release amphetamine products have been approved by the FDA for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old: Adzenys XR-ODT (Neos...
Two new extended-release amphetamine products have been approved by the FDA for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old: Adzenys XR-ODT (Neos Therapeutics), an orally distintegrating tablet, and Dyanavel XR (Tris Pharma), an oral suspension.
Med Lett Drugs Ther. 2016 Jun 20;58(1497):80-1 | Show Full IntroductionHide Full Introduction

QuilliChew ER - Extended-Release Chewable Methylphenidate Tablets

   
The Medical Letter on Drugs and Therapeutics • May 23, 2016;  (Issue 1495)
The FDA has approved a once-daily, extended-release chewable tablet formulation of methylphenidate (QuilliChew ER – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the...
The FDA has approved a once-daily, extended-release chewable tablet formulation of methylphenidate (QuilliChew ER – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first long-acting chewable formulation of the drug to be marketed in the US. Immediate-release chewable methylphenidate tablets (Methylin, and generics) have been available since 2003.
Med Lett Drugs Ther. 2016 May 23;58(1495):68-9 | Show Full IntroductionHide Full Introduction

Racemic Amphetamine Sulfate (Evekeo) for ADHD

   
The Medical Letter on Drugs and Therapeutics • September 28, 2015;  (Issue 1478)
The FDA has approved racemic amphetamine sulfate (Evekeo – Arbor) for oral treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥3 years old. It was also approved for treatment of...
The FDA has approved racemic amphetamine sulfate (Evekeo – Arbor) for oral treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥3 years old. It was also approved for treatment of narcolepsy in patients ≥6 years old and for short-term treatment of obesity in patients ≥12 years old.
Med Lett Drugs Ther. 2015 Sep 28;57(1478):137-8 | Show Full IntroductionHide Full Introduction

Aptensio XR - Another Long-Acting Methylphenidate for ADHD

   
The Medical Letter on Drugs and Therapeutics • July 20, 2015;  (Issue 1473)
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain...
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.
Med Lett Drugs Ther. 2015 Jul 20;57(1473):101-3 | Show Full IntroductionHide Full Introduction

Drugs for ADHD

   
The Medical Letter on Drugs and Therapeutics • March 16, 2015;  (Issue 1464)
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently persists into...
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently persists into adulthood. A recent study in a large Danish cohort found that ADHD was associated with increased mortality in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD has been reported to lower the risk of serious traffic accidents and criminal behavior.
Med Lett Drugs Ther. 2015 Mar 16;57(1464):37-40 | Show Full IntroductionHide Full Introduction

In Brief: Lisdexamfetamine (Vyvanse) for Binge Eating Disorder

   
The Medical Letter on Drugs and Therapeutics • March 16, 2015;  (Issue 1464)
Lisdexamfetamine dimesylate (Vyvanse), a prodrug of dextroamphetamine previously approved for treatment of attention-deficit/hyperactivity disorder, has now been approved for treatment of moderate-to-severe...
Lisdexamfetamine dimesylate (Vyvanse), a prodrug of dextroamphetamine previously approved for treatment of attention-deficit/hyperactivity disorder, has now been approved for treatment of moderate-to-severe binge eating disorder (recurrent episodes of compulsive overeating without purging) in adults.

FDA approval of lisdexamfetamine for this indication was based on two unpublished, 12-week trials, summarized in the package insert, that randomized patients with moderate-to-severe binge eating disorder to lisdexamfetamine 30 mg/day, which was titrated to 50 mg or, if needed, 70 mg, or to placebo. In both studies, patients treated with the active drug had a significantly greater reduction from baseline in binge days/week than those treated with placebo. In the first study (n=374), the placebo-subtracted difference was 1.35 binge days/week. In the second study (n=350), the difference was 1.66 binge days/week.

The recommended dosage of lisdexamfetamine for treatment of binge eating disorder is 30 mg/day, which can be titrated in 20-mg increments per week to a maximum of 70 mg/day. The cost of 30 days' treatment is about $217.1

Patients with eating disorders have an increased risk of overuse of stimulants for weight loss. The long-term effectiveness and safety of lisdexamfetamine in this population remain to be determined.

  1. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. March 5, 2015. Reprinted with permission by First Databank, Inc. All rights reserved. ©2015. www.fdbhealth.com/policies/drug-pricing-policy.


Download complete U.S. English article

Med Lett Drugs Ther. 2015 Mar 16;57(1464):42 | Show Full IntroductionHide Full Introduction

Quillivant XR - An Extended-Release Oral Suspension of Methylphenidate

   
The Medical Letter on Drugs and Therapeutics • February 4, 2013;  (Issue 1409)
The FDA has approved a once-daily, extended-release oral suspension of methylphenidate (Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first liquid...
The FDA has approved a once-daily, extended-release oral suspension of methylphenidate (Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first liquid formulation of the drug to be marketed for once-daily use. A short-acting oral solution (Methylin, and generics) has been available since 2003.
Med Lett Drugs Ther. 2013 Feb 4;55(1409):10-1 | Show Full IntroductionHide Full Introduction

Drugs for Treatment of ADHD

   
The Medical Letter on Drugs and Therapeutics • May 1, 2011;  (Issue 105)
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5% of school-age children, most often in boys, and frequently persists into young...
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5% of school-age children, most often in boys, and frequently persists into young adulthood.
Treat Guidel Med Lett. 2011 May;9(105):23-8 | Show Full IntroductionHide Full Introduction

Another Extended-Release Alpha2-Agonist for ADHD

   
The Medical Letter on Drugs and Therapeutics • February 7, 2011;  (Issue 1357)
The FDA has approved an extended-release formulation of clonidine hydrochloride (Kapvay– Shionogi) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. It is the second...
The FDA has approved an extended-release formulation of clonidine hydrochloride (Kapvay– Shionogi) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. It is the second alpha2-adrenergic agonist approved for this indication; guanfacine hydrochloride (Intuniv) was the first, but only clonidine is approved for use with stimulants.
Med Lett Drugs Ther. 2011 Feb 7;53(1357):10-2 | Show Full IntroductionHide Full Introduction

Guanfacine Extended-Release (Intuniv) for ADHD

   
The Medical Letter on Drugs and Therapeutics • October 18, 2010;  (Issue 1349)
An extended-release oral formulation of guanfacine hydrochloride (Intuniv – Shire), a selective alpha2A-adrenergic agonist, has been approved by the FDA for treatment of attention-deficit/hyperactivity...
An extended-release oral formulation of guanfacine hydrochloride (Intuniv – Shire), a selective alpha2A-adrenergic agonist, has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old.
Med Lett Drugs Ther. 2010 Oct 18;52(1349):82-3 | Show Full IntroductionHide Full Introduction

ECGs Before Stimulants in Children

   
The Medical Letter on Drugs and Therapeutics • July 28, 2008;  (Issue 1291)
The American Heart Association (AHA) recently published a statement saying that it would be reasonable to obtain an electrocardiogram (ECG) in children being evaluated for stimulant drug therapy for attention...
The American Heart Association (AHA) recently published a statement saying that it would be reasonable to obtain an electrocardiogram (ECG) in children being evaluated for stimulant drug therapy for attention deficit hyperactivity disorder (ADHD). A subsequent news release in conjunction with the American Academy of Pediatrics provided a clarification, saying that it would be reasonable to consider obtaining an ECG in such children.
Med Lett Drugs Ther. 2008 Jul 28;50(1291):60 | Show Full IntroductionHide Full Introduction

Lisdexamfetamine dimesylate (Vyvanse) for ADHD

   
The Medical Letter on Drugs and Therapeutics • July 16, 2007;  (Issue 1265)
Lisdexamfetamine dimesylate (Vyvanse - Shire), a prodrug in which d-amphetamine is covalently bonded to L-lysine, has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in...
Lisdexamfetamine dimesylate (Vyvanse - Shire), a prodrug in which d-amphetamine is covalently bonded to L-lysine, has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-12 years old. It was designed to have less potential than amphetamine itself for abuse, diversion or overdose toxicity. Like methylphenidate and amphetamines, lisdexamfetamine is a Schedule II controlled substance.
Med Lett Drugs Ther. 2007 Jul 16;49(1265):58-9 | Show Full IntroductionHide Full Introduction

Drugs for Treatment of ADHD

   
The Medical Letter on Drugs and Therapeutics • November 1, 2006;  (Issue 51)
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in 5-7% of school-age children and has also been estimated to occur in about 4% of adults. ADHD is characterized by...
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in 5-7% of school-age children and has also been estimated to occur in about 4% of adults. ADHD is characterized by a persistent pattern of frequent, severe inattention and/or hyperactivity/impulsivity that starts before the age of 7, is present in 2 or more settings (such as home and school), causes significant impairment in function, and is not caused by another mental disorder. The drugs approved for treatment of ADHD by the FDA are listed in this article. Except for atomoxetine, they are all stimulants and are classified as controlled substances by the US Drug Enforcement Administration (DEA).
Treat Guidel Med Lett. 2006 Nov;4(51):77-82 | Show Full IntroductionHide Full Introduction

Transdermal Methylphenidates (Daytrana) for ADHD

   
The Medical Letter on Drugs and Therapeutics • June 19, 2006;  (Issue 1237)
A transdermal patch formulation of methylphenidate (Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like...
A transdermal patch formulation of methylphenidate (Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like other methylphenidate products, the patch is a schedule II controlled substance. According to the manufacturer, it will be available in pharmacies by the end of June.
Med Lett Drugs Ther. 2006 Jun 19;48(1237):49-51 | Show Full IntroductionHide Full Introduction

In Brief: Adderall

   
The Medical Letter on Drugs and Therapeutics • March 28, 2005;  (Issue 1205)
On February 9, 2005, Health Canada suspended the marketing of Adderall XR (Shire), a mixture of amphetamine salts used to treat attention-deficit hyperactivity disorder (ADHD) (Med Lett Drugs Ther 1994;...
On February 9, 2005, Health Canada suspended the marketing of Adderall XR (Shire), a mixture of amphetamine salts used to treat attention-deficit hyperactivity disorder (ADHD) (Med Lett Drugs Ther 1994; 36:109). The immediate-release form of Adderall was never marketed in Canada. The withdrawal was based on 20 reports internationally of sudden death in patients taking the drug. These deaths, 14 of them in children, were not linked to overdose or abuse. The FDA decided that the number of sudden deaths was no greater than expected among the large number of people taking the drug, but because 5 of the children who died had structural heart defects, added a warning against using the drug in such patients. There is no evidence that Adderall offers any advantage over methylphenidate (Ritalin, and others) or dextroamphetamine (Dexedrine, and others), but some patients who do not respond satisfactorily to these drugs may respond to Adderall. Medical Letter consultants see no need to discontinue Adderall in patients who are taking it and doing well. For patients with a heart defect or a family history of sudden unexpected cardiovascular death, methylphenidate might be a better choice.
Med Lett Drugs Ther. 2005 Mar 28;47(1205):28 | Show Full IntroductionHide Full Introduction

Atomoxetine (Strattera) Revisited

   
The Medical Letter on Drugs and Therapeutics • August 16, 2004;  (Issue 1189)
Atomoxetine (Strattera - Lilly), a nonstimulant drug that is not a controlled substance, was approved by the FDA in early 2003 for the treatment of attention deficit hyperactivity disorder (ADHD). At that time,...
Atomoxetine (Strattera - Lilly), a nonstimulant drug that is not a controlled substance, was approved by the FDA in early 2003 for the treatment of attention deficit hyperactivity disorder (ADHD). At that time, The Medical Letter concluded that it was unclear whether atomoxetine was as effective as stimulants such as methylphenidate (Concerta, and others) (Medical Letter 2003; 45:11). Since then, the drug has been heavily advertised directly to the public for use in both children and adults.
Med Lett Drugs Ther. 2004 Aug 16;46(1189):65 | Show Full IntroductionHide Full Introduction

Atomoxetine (Strattera) for ADHD

   
The Medical Letter on Drugs and Therapeutics • February 3, 2003;  (Issue 1149)
Atomoxetine (Strattera - Lilly) is the first non-stimulant drug to be approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD). Unlike other drugs approved for use in ADHD, it is not...
Atomoxetine (Strattera - Lilly) is the first non-stimulant drug to be approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD). Unlike other drugs approved for use in ADHD, it is not a controlled substance and is approved for use in adults as well as children. Older non-stimulant drugs that have been used to treat ADHD, although not FDA-approved, include the alpha2-agonist clonidine (Catapres, and others) and the tricyclic antidepressant desipramine (Norpramin, and others) (Medical Letter 1996; 38:109).
Med Lett Drugs Ther. 2003 Feb 3;45(1149):11-2 | Show Full IntroductionHide Full Introduction

Another long-acting Methylphenidate (Metadate CD)

   
The Medical Letter on Drugs and Therapeutics • October 1, 2001;  (Issue 1114)
Methylphenidate is now available in a new extended-release formulation (Metadate CD - Celltech) for treatment of attention deficit/hyperactivity disorder (ADHD). The new product, which is a Schedule II...
Methylphenidate is now available in a new extended-release formulation (Metadate CD - Celltech) for treatment of attention deficit/hyperactivity disorder (ADHD). The new product, which is a Schedule II controlled substance, is being advertised directly to consumers.
Med Lett Drugs Ther. 2001 Oct 1;43(1114):83-4 | Show Full IntroductionHide Full Introduction

A New Long-acting Methylphenidate (Concerta)

   
The Medical Letter on Drugs and Therapeutics • September 4, 2000;  (Issue 1086)
Methylphenidate (Ritalin, and others) is now available in a new extended-release formulation (Concerta--Alza) for treatment of attention deficit/hyperactivity disorder...
Methylphenidate (Ritalin, and others) is now available in a new extended-release formulation (Concerta--Alza) for treatment of attention deficit/hyperactivity disorder (ADHD).
Med Lett Drugs Ther. 2000 Sep 4;42(1086):80-1 | Show Full IntroductionHide Full Introduction

Adderall and Other Drugs for Attention-Deficit/Hyperactivity Disorder

   
The Medical Letter on Drugs and Therapeutics • November 25, 1994;  (Issue 936)
A drug that combines the neutral sulfate salts of dextroamphetamine and racemic amphetamine with the dextro isomer of amphetamine saccharate and d,l amphetamine aspartate (Adderall - Richwood Pharmaceutical)...
A drug that combines the neutral sulfate salts of dextroamphetamine and racemic amphetamine with the dextro isomer of amphetamine saccharate and d,l amphetamine aspartate (Adderall - Richwood Pharmaceutical) has recently been promoted for treatment of children with Attention-Deficit/Hyperactivity Disorder (ADHD). This same mixture of amphetamine salts was previously marketed as Obetrol for treatment of obesity.
Med Lett Drugs Ther. 1994 Nov 25;36(936):109-10 | Show Full IntroductionHide Full Introduction